司库奇尤单抗治疗活动性银屑病关节炎患者的最低疾病活动度:多中心、随机、双盲、平行组、安慰剂对照III期研究2年结果
FUTURE 2研究评估活动性银屑病关节炎患者接受司库奇尤单抗治疗至2年的最低疾病活动度(MDA)。第16周时,司库奇尤单抗300 mg和150 mg组MDA达标率分别为28%和23%,安慰剂组为10%;抗TNF初治者达标率更高。MDA应答在2年内持续,且与生活质量等患者报告结局改善相关。
要点
- 第16周MDA达标率:司库奇尤单抗300 mg组28%、150 mg组23%,安慰剂组10%。
- 抗TNF初治队列第16周MDA达标率:300 mg组34%、150 mg组32%,安慰剂组13%。
- 司库奇尤单抗300 mg和150 mg的MDA与VLDA应答持续至2年。
核心结论
- 第16周时司库奇尤单抗组MDA达标比例高于安慰剂组,且应答率持续至2年。
- MDA与患者报告结局(包括生活质量)改善相关,并持续至2年。
研究设计与样本
- FUTURE 2为多中心、随机、双盲、平行组、安慰剂对照III期研究,活动性银屑病关节炎患者随机接受皮下司库奇尤单抗300、150或75 mg或安慰剂。
- 在总体人群(抗TNF初治和抗TNF应答不佳者)及按既往抗TNF暴露和诊断时间分层患者中,于第16、24、52和104周评估MDA。
- 在MDA应答者与非应答者中评估功能及患者报告结局,包括健康相关生活质量和工作效率。
主要发现
- 第16周MDA达标率:司库奇尤单抗300 mg组28%(27/98)、150 mg组23%(23/100),安慰剂组10%(9/94)。
- 抗TNF初治队列第16周MDA达标率:司库奇尤单抗300 mg组34%、150 mg组32%,安慰剂组13%。
- 抗TNF应答不佳队列第16周MDA达标率:司库奇尤单抗300 mg组15%、150 mg组8%,安慰剂组3%。
- 第16周MDA应答者中27.1%(16/59)达到VLDA;司库奇尤单抗300 mg组30%(8/27)、150 mg组26%(6/23),安慰剂组22%(2/9),数值上更高。
- 司库奇尤单抗300 mg和150 mg的MDA与VLDA应答持续至2年;MDA应答者较非应答者在生活质量结局上改善更大,持续至2年。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate minimal disease activity (MDA) among psoriatic arthritis (PsA) patients receiving secukinumab through 2 years in the FUTURE 2 study. METHODS: Patients with active PsA were randomized to receive subcutaneous secukinumab 300, 150, or 75 mg or placebo. MDA was assessed in the overall population (anti-tumor necrosis factor [anti-TNF]-naive and inadequate responders [anti-TNF-IR]) and in patients stratified by prior anti-TNF exposure and by time since diagnosis at weeks 16, 24, 52, and 104. Function and patient-reported outcomes (PROs), including health-related quality of life (QoL) and work productivity, were assessed in MDA responders versus nonresponders. RESULTS: Overall, 28% of patients (27 of 98) and 23% (23 of 100) achieved MDA at week 16 with secukinumab 300 and 150 mg, respectively, versus 10% (9 of 94) with placebo. In the anti-TNF-naive cohort, a higher proportion of patients achieved MDA at week 16 with secukinumab 300 and 150 mg (34% and 32%, respectively) versus placebo (13%). The corresponding value in the anti-TNF-IR cohort was 15% and 8% with secukinumab 300 and 150 mg, respectively, versus with placebo (3%). At week 16, 27.1% of MDA responders (16 of 59) achieved a very low disease activity (VLDA) response, with the percentage being numerically greater with secukinumab 300 and 150 mg (30% [8 of 27] and 26% [6 of 23], respectively) versus placebo (22% [2 of 9]). The MDA and VLDA responses with secukinumab 300 and 150 mg were sustained through 2 years. MDA responders showed greater improvements in QoL outcomes compared to nonresponders through 2 years. CONCLUSION: A greater proportion of patients achieved MDA with secukinumab versus placebo at week 16, with response rates sustained through 2 years. MDA was associated with improved PROs, including QoL, through 2 years.
引用
- Coates LC, Mease PJ, Gossec L, et al. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. Arthritis Care Res (Hoboken). 2018. PMID: 29409133. doi:10.1002/acr.23537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。